New study tracks IBD patients on biosimilar drug hyrimoz®

NCT ID NCT05633771

Ongoing Knowledge-focused Sponsor: Sandoz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 562 adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are starting or switching to Hyrimoz®, a biosimilar of adalimumab. Researchers will track how many patients continue the treatment after 6 months and why some stop, such as lack of effect, side effects, or personal choice. The goal is to understand real-world use, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASE

Contacts and locations

Show contact details

Locations

Sandoz Investigational Site Belgium

Aalst, Belgium
Sandoz Investigational Site Belgium

Antwerp, Belgium
Sandoz Investigational Site Belgium

Bonheiden, Belgium
Sandoz Investigational Site Belgium

Brussels, Belgium
Sandoz Investigational Site Belgium

Eeklo, Belgium
Sandoz Investigational Site Belgium

Ghent, Belgium
Sandoz Investigational Site Belgium

Herentals, Belgium
Sandoz Investigational Site Belgium

Kortrijk, Belgium
Sandoz Investigational Site Belgium

Liège, Belgium
Sandoz Investigational Site Belgium

Namur, Belgium
Sandoz Investigational Site Belgium

Seraing, Belgium
Sandoz Investigational Site Belgium

Sint-Niklaas, Belgium
Sandoz Investigational Site Belgium

Tongeren, Belgium
Sandoz Investigational Site France

Amiens, France
Sandoz Investigational Site France

Auxerre, France
Sandoz Investigational Site France

Bayonne, France
Sandoz Investigational Site France

Beauvais, France
Sandoz Investigational Site France

Brest, France
Sandoz Investigational Site France

Caen, France
Sandoz Investigational Site France

Castelnau-le-Lez, France
Sandoz Investigational Site France

Clermont-Ferrand, France
Sandoz Investigational Site France

Clichy, France
Sandoz Investigational Site France

Cornebarrieu, France
Sandoz Investigational Site France

Créteil, France
Sandoz Investigational Site France

Gien, France
Sandoz Investigational Site France

Le Coudray, France
Sandoz Investigational Site France

Le Kremlin-Bicêtre, France
Sandoz Investigational Site France

Lille, France
Sandoz Investigational Site France

Lyon, France
Sandoz Investigational Site France

Marseille, France
Sandoz Investigational Site France

Montpellier, France
Sandoz Investigational Site France

Nancy, France
Sandoz Investigational Site France

Neuilly-sur-Seine, France
Sandoz Investigational Site France

Nice, France
Sandoz Investigational Site France

Nîmes, France
Sandoz Investigational Site France

Orléans, France
Sandoz Investigational Site France

Paris, France
Sandoz Investigational Site France

Pessac, France
Sandoz Investigational Site France

Pierre-Bénite, France
Sandoz Investigational Site France

Poitiers, France
Sandoz Investigational Site France

Pringy, France
Sandoz Investigational Site France

Reims, France
Sandoz Investigational Site France

Rennes, France
Sandoz Investigational Site France

Saint-Etienne, France
Sandoz Investigational Site France

Saint-Nazaire, France
Sandoz Investigational Site France

Sarrebourg, France
Sandoz Investigational Site France

Toulouse, France
Sandoz Investigational Site France

Tours, France
Sandoz Investigational Site France

Troyes, France
Sandoz Investigational Site France

Vandœuvre-lès-Nancy, France
Sandoz Investigational Site France

Vénissieux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.